Mainz Biomed Announces Pricing of Follow-On Offering to Raise Approximately $3.0 Million

Strategic Insights -

Mainz Biomed, a molecular genetics diagnostic company, has announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share or a pre-funded warrant and one Series A warrant to purchase one and a half ordinary shares. The offering is expected to raise approximately $3.0 million and will be used to support the development and commercialization of the Company's products, including its flagship product, ColoAlert.

Key Takeaways:

  • The follow-on offering will consist of 2,222,222 units, with each unit priced at $1.35.
  • The gross proceeds from the offering are expected to be approximately $3.0 million.
  • The newly issued securities will be offered pursuant to a registration statement on Form F-1, as amended, which was declared effective by the SEC on August 4, 2025.
  • The offering is being made only by means of a prospectus which is a part of the Registration Statement.
  • The Company's flagship product, ColoAlert, is an accurate, non-invasive, and easy-to-use diagnostic test for colorectal cancer.
  • ColoAlert is marketed across Europe and the Company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval.
  • The Company's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples.

Statistics:

  • 2,222,222 units will be issued in the follow-on offering.
  • The effective offering price is $1.35 per unit.
  • The gross proceeds from the offering are expected to be approximately $3.0 million.
  • The Registration Statement was declared effective by the SEC on August 4, 2025.
  • The Company's flagship product, ColoAlert, has been marketed across Europe since [date not specified].
  • The Company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval.
  • The Company's product candidate portfolio includes PancAlert, which is an early-stage pancreatic cancer screening test.

Sources:

  • GlobeNewswire (August 4, 2025)
  • Registration Statement on Form F-1, as amended (File No. 333-289095)
  • The Company's official website at mainzbiomed.com/investors/